AIDSInfo: New HIV Drug, New Panel Members

AIDSInfo: New HIV Drug, New Panel Members

Thursday, February 22, 2018
TARGET Center

The February 22, 2018 issue of AIDSInfo's At-a-Glance provides updates on a new HIV combination therapy for treatment-naive adults and a welcome message for new members of the HHS adult/adolescent antiretroviral guidelines panel.

Subscribe to AIDSInfo's At-a-Glance E-News.

  • The treatment regimen, Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide), was approved by FDA February 8 and is the latest of around 50 drugs/combination regimens approved for use as HIV antiretroviral agents (see infographic below).
  • The seven new panel members of the HHS Panel on Antiretroviral Guidelines for Adults and Adolescents are from agencies that deliver HIV care to underserved populations via HRSA Ryan White HIV/AIDS Program funding. Learn more about the guidelines.
    FDA approvals of HIV antiretrovirals